NEW YORK (GenomeWeb News) – Exosome Diagnostics today said that Promega will be the exclusive supplier of its Urine Clinical Sample Concentrator Kit, which incorporates Exosome's technology for concentration of urinary exosomes.

The kit is sued for molecular diagnostic applications, and New York-based Exosome said that it will be used to process urine samples for clinical trials in genitourinary disorders, such as prostate cancer. Financial and other terms of the agreement weren't disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.